Dihydrotestosterone (DHT)

Name: Dihydrotestosterone (DHT)
Brand: Selleck Chemicals
SKU: S4757
Rating: 5 (6 reviews)

For research use only.

Catalog No.S4757 Synonyms: androstanolone, stanolone, 5α-DHT

6 publications

Dihydrotestosterone (DHT) Chemical Structure

CAS No. 521-18-6

Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.

Selleck's Dihydrotestosterone (DHT) has been cited by 6 publications

Environ Health Perspect, 2021, 129(4):47010

PubMed: 33851871 ( click the link to review the publication )

Hum Reprod, 2020, 6 pii: deaa077

PubMed: 32372097 ( click the link to review the publication )

Prostate, 2020, 80(9):674-686

PubMed: 32294305 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 21;526(1):267-272

PubMed: 32209261 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:9821-9837

PubMed: 33061460 ( click the link to review the publication )

Circulation, 2019, 140(13):1070-1080

PubMed: 31378084 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description

Targets

Androgen Receptor ^[1]
()

In vitro

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells^[1].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CV-1 cell	NXrNWXpPTnWwY4Tpc44h[XO\|YYm=			NUXzPXl{SWexbnnzeIlkKGGldHn2bZR6KCiHQ{WwLUBi\2GrboP0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXi1zIHPlcIwtKEWFNUC9NE4xODZizszN	M{HOSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6N{G1N\|QoRjl6N{G1N\|Q9N2F-
MDA-MB-453 cell	MXfGeY5kfGmxbjDhd5NigQ>?			NE\XdpNFcXOybHHj[Y1mdnRib3[gX\|NJZUSKVDDmdo9uKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCPRFGtUWIuPDV\|IHPlcIx{KGK7IIfoc4xmKGOnbHygdoVk\XC2b4KgZolv\GmwZzDhd5NigSxiS3m9NE4xODB{IN88US=>	Ml;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNVcoRjF5MEO0NVE4RC:jPh?=
HepG2 cell	NWriW3VFTnWwY4Tpc44h[XO\|YYm=			NF7peVdC[3Srdnn0fUBi\2GrboP0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYXP0bZZifGmxbjygTWM2OD1yLkCxPFIh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF2OUi2Okc,OTdzNEm4OlY9N2F-
MDA453 cell	MXrGeY5kfGmxbjDhd5NigQ>?			M37WT2Rqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gRXIhcW5iTVTBOFU{KGOnbHzzMEBMcT1yLkCwN{DPxE1?	MmC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzOEGxOFEoRjF5MUixNVQyRC:jPh?=
mouse C2C12 cell	MYnGeY5kfGmxbjDhd5NigQ>?			MUnB[49vcXO2IHHjeIl3cXS7IHH0JJJifCCDUjD0doFve2[nY4Tl[EBqdiCvb4Xz[UBEOkNzMjDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NF0xNjB{ODFOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF6MUG0NUc,OTdzOEGxOFE9N2F-
monkey COS7 cell	NIPZW\|NHfW6ldHnvckBie3OjeR?=			M3jPdWJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKG2xbnvlfUBEV1N5IHPlcIx{KGK7IIfoc4xmKGOnbHygZolv\GmwZzDhd5NigSxiS3m9NE4xODB{IN88US=>	NW\PZoNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OFI6OTJpPkG4OFQzQTF{PD;hQi=>
CHO cell	M2OzO2Z2dmO2aX;uJIF{e2G7			MnT0RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUS3I2KGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZpkhdHWlaX\ldoF{\SCjc4PhfUwhTUN3ME20MlQ6KM7:TR?=	M4f5O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C3Nlk1Lz5zOEOwO\|I6PDxxYU6=
COS7 cell	NFPBRY1HfW6ldHnvckBie3OjeR?=			Mn\XRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDXO\|QySyCvdYThcpQh\XiycnXzd4VlKGmwIFPPV\|ch[2WubIOgZZN{\XO\|ZXSgZZMhdHWlaX\ldoF{\SCjY4Tpeol1gSCjZoTldkAzPCCqcoOgZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzMjFOwG0>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7NEK3PUc,OjJyOUSyO\|k9N2F-
COS7 cell	MY\GeY5kfGmxbjDhd5NigQ>?			M{XCbGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgWFg4P0FibYX0ZY51KGW6cILld5Nm\CCrbjDDU3M4KGOnbHzzJIF{e2W\|c3XkJIF{KGy3Y3nm[ZJie2ViYXP0bZZqfHliYX\0[ZIhOjRiaILzJIJ6KHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yMUWg{txO	NIrXfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
COS7 cell	NUnVZ4xtTnWwY4Tpc44h[XO\|YYm=			NGjSZo9C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFT2O3JINmdGy\|IHHzd4V{e2WmIHHzJIx2[2moZYLhd4Uh[WO2aY\peJkh[W[2ZYKgNlQhcHK\|IHL5JJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xODZ{IN88US=>	NUS1TVNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVQzPzlpPkKyNFk1Ojd7PD;hQi=>
LNCaP-hr cell	MWPGeY5kfGmxbjDhd5NigQ>?		NFTTWZE{KGSjeYO=	NIntWGlC\2:waYP0JIFkfGm4aYT5JIF1KEGwZILv[4VvKHKnY3XweI9zKFR6N{fBJI12fGGwdDDpckBpfW2jbjDMUmNiWC2qcjDj[YxteyCjc4Pld5Nm\CCjczDwdo9{fGG2ZTDzdIVkcW[rYzDhcpRq\2WwIIPlZ5JmfGmxbjDt[YF{fXKnZDDh[pRmeiB\|IHThfZMh[nliZX76fY1mNWmvbYXuc4F{e2G7LDDFR\|UxRTBwMEG1JO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF7OUS3O{c,OjNzOUm0O\|c9N2F-
LNCaP-hr cell	NGnsS5lHfW6ldHnvckBie3OjeR?=		NFn2OXc{KGSjeYO=	M4PY[mFod26rc4SgZYN1cX[rdImgZZQhf2muZDD0fZBmKEGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKEyQQ3HQMYhzKGOnbHzzJIF{e2W\|c3XkJIF{KHC{b4P0ZZRmKHOyZXPp[olkKGGwdHnn[Y4he2WlcnX0bY9vKG2nYYP1doVlKGGodHXyJFMh\GG7czDifUBmdnq7bXWtbY1ufW6xYYPzZZktKEWFNUC9NE4xODZ{IN88US=>	NHLJb5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
HEK293 cell	MXLGeY5kfGmxbjDhd5NigQ>?			M4jiNmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5zODDuUS=>	MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEW2PFgoRjJ3M{C1Olg5RC:jPh?=
COS	MoHHSpVv[3Srb36gZZN{[Xl?			M{jLXGJqdmSrbnegZYZncW6rdImgZYdicW6\|dDDBcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO\|ZXSgR29UKGOnbHzzMEBMcSB;IECuNFAzKM7:TT6=	M2L6RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6N{G1N\|QoRjl6N{G1N\|Q9N2F-
COS-1	MYjGeY5kfGmxbjDhd5NigQ>?			NUWyXpVzSmmwZHnu[{Bi\m[rbnn0fUBnd3JiaIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzMEBMcSB;IECuNFA{KM7:TT6=	NGnQUGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OUK1O\|I2Lz57OUK1O\|I2RC:jPh?=
CV-1	MnjCSpVv[3Srb36gZZN{[Xl?			MlewRYdwdmm\|dDDhZ5Rqfmm2eTDh[4FqdnO2IFj1cYFvKEGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDWk0yKGOnbHzzMEBGSzVyIE2gNE4xODVizszNMi=>	MorKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTl{NUeyOUc,QTl{NUeyOVww[T5?
COS	M165eGZ2dmO2aX;uJIF{e2G7			NHHPcFJKdiC4aYTyc{BjcW6maX7nJIFn\mmwaYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJJRz[W6\|ZnXjeIVlKGmwdH:gR29UKGOnbHzzMkwhUUN3MDC9JFAvODB2IN88UU4>	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB{M{C2NlgoRjFyMkOwOlI5RC:jPh?=
CV-1	MkP0SpVv[3Srb36gZZN{[Xl?			NX\CNpFDUW5idnn0do8h[WexbnnzeIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgeZNqdmdiY3;0doFve2[nY4Tpc44h[XO\|YYmgbY4hS1ZvMTDj[Yxtey5uIFXDOVAhRSByLkCwOkDPxE1w	NE\PcGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEKzNFYzQCd-MUCyN\|A3Ojh:L3G+
CV-1	NEH1dW9HfW6ldHnvckBie3OjeR?=			Ml3KRYdwdmm\|dDDhZ5Rqfmm2eTD0c{B1cGViaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5IhMGiDUjmgbY4hS1ZvMTDj[YxteyxiRVO1NEA:KDBwMEC2JO69VS5?	NGO1Vno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEO0NFYzPCd-MUCzOFA3OjR:L3G+
CV1	NVnSZWRKTnWwY4Tpc44h[XO\|YYm=			MmDVRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDpckBEXjFiY3XscJMhdWWjc4Xy[YQh[XNic4TpcZVt[XSrb36gc4YhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5JIJ6KGOxdILhcpNn\WO2aX;uJIF{e2G7LDDFR\|UxKD1iMD6wNFUyKM7:TT6=	MorqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNVcoRjF5MEO0NVE4RC:jPh?=
CV1	M2PROmZ2dmO2aX;uJIF{e2G7			MUnCbY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMtKEurIE2gNE4xODB{IN88UU4>	NHzPPY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1O\|g{QCd-MUeyOVc5Ozh:L3G+
CV1	MnzoSpVv[3Srb36gZZN{[Xl?			MVLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMtKEWFNUCgQUAxNjByNUGg{txONg>?	M3;yOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW3PFM5Lz5zN{K1O\|g{QDxxYU6=
MDA-MB-453	MWLGeY5kfGmxbjDhd5NigQ>?			NX32[GRETGm\|cHzhZ4Vu\W62IH;mJHs{UF2GSGSg[pJwdSCqdX3hckBCWiCneIDy[ZN{\WRiaX6gUWRCNU2ELUS1N{Bk\WyuczygT4khRSByLkCwNFMh\|ryPLh?=	M{PUNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEO5NVEzLz5zN{SzPVEyOjxxYU6=
CV1	NFewOolHfW6ldHnvckBie3OjeR?=			MXTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMh[nlidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjByNUeg{txONg>?	NV6wRpdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0N\|kyOTJpPkG3OFM6OTF{PD;hQi=>
CV1	NUm2TJBZTnWwY4Tpc44h[XO\|YYm=			NH;x[JpC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFVkGgZ4VtdHNiYomgeJJidnOlcnnweIlwdmGuIHHjeIl3[XSrb36gZZN{[XluIFXDOVAhRSByLkCwOVch\|ryPLh?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzdyM{mzPEc,OTd5MEO5N\|g9N2F-
MDA-MB-453	M3LZd2Z2dmO2aX;uJIF{e2G7			M{iwW2Rqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gRY5lem:pZX6gdoVk\XC2b4KgbY4hcHWvYX6gUWRCNU2ELUS1N{Bk\WyuczygT4khRSByLkCwNFkh\|ryPLh?=	NWTydId7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFA1QTlpPkG4OFAxPDl7PD;hQi=>
CV1	M1HuOWZ2dmO2aX;uJIF{e2G7			MlK2RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDpckBEXjFiY3XscJMh[nlidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjByNUeg{txONg>?	NH;ycpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESwNFQ6QSd-MUi0NFA1QTl:L3G+
Saos2	M3W0dWZ2dmO2aX;uJIF{e2G7			M4T2NWFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKFOjb4OyJINmdGy\|IHHzd4V{e2WmIHHzJGlNPiC{ZYDy[ZN{cW:wLDDJR\|UxKD1iMD6wNFAxPSEQvF2u	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR2MkmxNkc,OTh2NEK5NVI9N2F-
CV1	MWXGeY5kfGmxbjDhd5NigQ>?			Moq5RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[nliY3;0doFve2[nY4Tpc44h[XO\|YYmsJGVEPTBiPTCwMlAxPTFizszNMi=>	M3rkclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NESyPVEzLz5zOES0NlkyOjxxYU6=
MDA-kb2	M3nTPGZ2dmO2aX;uJIF{e2G7			NXTJZ2pSSWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCPRFGtb4IzKGOnbHzzJIF{e2W\|c3XkJIF{KHO2aX31cIF1cW:wIH;mJIx2[2moZYLhd4Uh[WO2aY\peJkh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzF3MDC9JFAvODByNTFOwG0v	NEHxOlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW5NlI1PSd-MUm1PVIzPDV:L3G+
MDA-kb2	NIDKV\|NHfW6ldHnvckBie3OjeR?=			MmDjRYdwdmm\|dDDhZ5Rqfmm2eTDheEBodHWlb3PvdpRq[2:rZDDy[YNmeHSxcjDpckBpfW2jbjDNSGEuc2J{IHPlcIx{KGG\|c3Xzd4VlKGG\|IIP0bY12dGG2aX;uJI9nKGy3Y3nm[ZJie2ViYXP0bZZqfHliYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{G1NEA:KDBwMECwOUDPxE1w	NHP0OYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW5NlI1PSd-MUm1PVIzPDV:L3G+
MDA-MB-453	MV3GeY5kfGmxbjDhd5NigQ>?			MV7EbZNxdGGlZX3lcpQhd2ZiW{PIYY1mfGi7bITybYVvd2yxbnWg[pJwdSCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCPRFGtUWIuPDV\|IHPlcIx{NCCLQ{WwJF0hOC5yMEGg{txONg>?	NVrvbIdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2NFY5PzBpPkG5OlA3QDdyPD;hQi=>
MDA-MB-453	NVe4UWtTTnWwY4Tpc44h[XO\|YYm=			MUXB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJIlvKGi3bXHuJG1FSS2PQj20OVMh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDNUXRXNUyXQzDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiTV3UWk1NXFJxcILvcY91\XJibHnub4VlKEyXQzDn[Y5mKGK7IHz1Z4ln\XKjc3WgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5yMEKg{txONg>?	M4fGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkC2PFcxLz5zOU[wOlg4ODxxYU6=
NIH3T3	NW[5XmpGTnWwY4Tpc44h[XO\|YYm=			NXGzXpkySWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCOQlSgWFg4P0FibYX0ZY51KGmwIH3veZNmKE6LSEPUN{Bk\WyuczD0doFve2mnboTsfUB1emGwc3\lZ5Rm\CC5aYToJIJmfGFvZ3HsZYN1d3OrZHHz[UBz\XCxcoTldkBo\W6nIHHzd4V{e2WmIHHzJINmdGy3bHHyJJRz[W6\|Zn;ycYF1cW:wIHL5JHIuW0GWIHHzd4F6NCCHQ{WwJF0hOC5yMEGyOVkh\|ryPLh?=	MlvnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6NU[5NlEoRjF7OEW2PVIyRC:jPh?=
NIH3T3	MXPGeY5kfGmxbjDhd5NigQ>?			MVXB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJIlvKG2xdYPlJG5KUDOWMzDj[YxteyC2cnHud4lmdnSueTD0doFve2[nY4Tl[EB4cXSqIHLleIEu\2GuYXP0c5Nq\GG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3Xzd4VlKGG\|IHPlcIx2dGG{IITyZY5{\m:{bXH0bY9vKGK7IGKtV2FVKGG\|c3H5MEBGSzVyIE2gNE4xODN7OEGg{txONg>?	NVT6XlBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4OVY6OjFpPkG5PFU3QTJzPD;hQi=>
COS7	NHLiNpVHfW6ldHnvckBie3OjeR?=			MmnrRYdwdmm\|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEORU{egZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDHZYw1NUSERDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCyJO69VS5?	NGrEWWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi2N\|A5Oyd-MUm4OlMxQDN:L3G+
Freestyle293F	NIrXOmlHfW6ldHnvckBie3OjeR?=		NVe5dVRIOyCqcoO=	NETrOFNFcXOybHHj[Y1mdnRib3[gX\|E4NWGucHjhMY1mfGi7bD2zTH0udWmkb3zldo9v\SCocn;tJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOg[IVzcX[nZDDGdoVmW3S7bHWyPVNHKGOnbHzzJIFnfGW{IEOgbJJ{NCCLQ{WwJF0hOC5yMEKxJO69VS5?	M3XzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEm0Nlc6Lz5{MkC5OFI4QTxxYU6=
Freestyle293F	M{Pz[WZ2dmO2aX;uJIF{e2G7		MYSzJIhzew>?	MoXLSIl{eGyjY3Xt[Y51KG:oIGuxO{1idHCqYT3t[ZRpgWxvM1jdMY1q[m:uZYLvcoUh\nKxbTDoeY1idiCjbnTyc4dmdiC{ZXPldJRweiCWOEe3RUBufXSjboSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bl\XKrdnXkJGZz\WWVdIns[VI6O0ZiY3XscJMh[W[2ZYKgN{BpenNuIFnDOVAhRSByLkCwNlYh\|ryPLh?=	MmTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO\|koRjJ{MEm0Nlc6RC:jPh?=
HeLa	NUG3UYdyTnWwY4Tpc44h[XO\|YYm=			NYTI[4FVXHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJJRz[W6\|ZnXjeIVlKGmwIHj1cYFvKEinTHGgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCDY4Tpeol1gSB;IECuNFA5KM7:TT6=	M3T3SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEm3OlEyLz5{Mki5O\|YyOTxxYU6=
HeLa	NGX6WWxHfW6ldHnvckBie3OjeR?=			NGTuV\|FR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEinTHGgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BCWkViYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHLhd4VlKHS{YX7zZYN1cX[jdHnvckBie3OjeTygRYN1cX[rdImgQUAxNjByODFOwG0v	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3N{m0O{c,OjJ7NUe5OFc9N2F-
Freestyle293F	MoDQSpVv[3Srb36gZZN{[Xl?			NXGyWFE4UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgRY5lem:pZX6gdoVk\XC2b4KgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hTnKnZYP0fYxmOjl\|RjDj[YxteyxiSVO1NEA:KDBwMECyNUDPxE1w	NFrxVGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
Freestyle293F	NYL4N2k6TnWwY4Tpc44h[XO\|YYm=			NHrlfI9KdmirYnn0bY9vKG:oIFHu[JJw\2WwIILlZ4VxfG:{IGS4O\|dCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCIcnXld5R6dGV{OUPGJINmdGy\|LDDJR\|UxKD1iMD6wNFI3KM7:TT6=	MoLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOUm0O\|coRjJ\|MUm5OFc4RC:jPh?=
COS7	NX36O4k{TnWwY4Tpc44h[XO\|YYm=		NGr4dG4zKGi{cx?=	Mm\jSIl{eGyjY3Xt[Y51KG:oIGuzTH0hZTWjbIDoZU1FUFRiZoLvcUBud3W\|ZTDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hdW:wa3X5JGNQWzdiY3XscJMh[W[2ZYKgNkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCjbnHsfZNqeyxiSVO1NEA:KDBwMECxJO69VS5?	M{O5d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUK3PFE3Lz5{M{WyO\|gyPjxxYU6=
C2C12	M{mxN2Z2dmO2aX;uJIF{e2G7		MVO1JIRigXN?	NGjHc4xC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDtc5V{\SCFMlOxNkBk\WyuczDhd5Nme3OnZDDhd{Bwe3Snb3LsZZN1KGSrZn\ldoVvfGmjdHnvckBi\nSncjC1JIRigXNuIFXDOVAhRSByLkCwNFA2KM7:TT6=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK5NEc,OjR7MECyPVA9N2F-
C2C12	NWrUbJp1TnWwY4Tpc44h[XO\|YYm=			NX\yT5JLSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5ibX;1d4UhSzKFMUKgZ4VtdHNiYomgZY5lem:pZX6td5Bm[2moaXOgdoV{eG:wc3Wg[YxmdWWwdD3kdol3\W5ibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyIE2gNE4xODBzMzFOwG0v	M4iyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKxPVY1Lz5{NUGyNVk3PDxxYU6=
COS7	M1;NPWZ2dmO2aX;uJIF{e2G7		NH;oSYQzPCCqcoO=	MofLRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDBVkBmgHC{ZYPz[YQhcW5iQX\ybYNidiCpcnXlckBud26tZYmgR29UPyClZXzsd{Bi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC5yMEOg{txONg>?	Mlv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NUS4OFkoRjJ6NEW0PFQ6RC:jPh?=
Shionogi	M4fjc2Z2dmO2aX;uJIF{e2G7	M4XHdVExKHCP		NHHLNVRKdmS3Y4Tpc44hd2ZicILvcIln\XKjdHnvckBw\iCvb4Xz[UBUcGmxbn;nbUBk\WyuczDheEAyOCCyTR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzdzMUi1OUc,OTd5MUG4OVU9N2F-
MCF7	M4P0bmZ2dmO2aX;uJIF{e2G7	MWOzNEB2VQ>?	NXPkNJRWOjRiaILz	MmTwRY51[WexbnnzeEBi[3Srdnn0fUBifCCDUjDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBVkBt\X[nbDDheEA{OCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w>	M{WzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEG0O\|UyLz5{MkCxOFc2OTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / Cyclin D2 / Cyclin D3 / Cyclin E2 / Cyclin A1 / AR; PubMed: 26372468 PLoS One HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h), and immunoblot analysis of cell lysates reveals that cyclin D1 and D2 protein expression decreased substantially with DHT treatment compared to vehicle. p-CDK2 / CDK2 / CDK4 / CDK6 / CDKN1A / p-RB / RB ; PubMed: 26372468 PLoS One HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h). Immunoblot analysis of cell lysates reveals that CDK4 and CDK6 protein expression decreased and CDKN1A expression increased with DHT treatment compared to vehicle. CDK2 phosphorylation at threonine 160 (T160) decreased nearly 50% with androgen treatment at 24 and 48 hours, albeit not significantly, and total CDK2 protein expression remained unchanged. Relative to total RB expression, the levels of various phosphorylated forms of RB (S780 and S807/811) decreased over time with androgen treatment. p27 / p-p27 ; PubMed: 22139837 J Biol Chem CWR22Rv1 or CWR22R3 cells were stimulated with 10 nm DHT for 6 h, with the addition of MG132 during the last 2 h before harvesting. Proteins were then immunoblotted. AR / PP1 ; PubMed: 26636645 Oncotarget HeLa cells were transfected with Flag-PP1α and HA-AR and then incubated for overnight in androgen-depleted medium without or with androgen (10 nM of DHT) as indicated for blotting.	26372468 22139837 26636645
Immunofluorescence	FOXO1 / p27 ; PubMed: 22139837 J Biol Chem CWR22R3 cells cultured in medium with CDS serum were treated without/with DHT (10 nm) for 4 h. The cells were immunostained for FOXO1 and p27 and examined with a confocal microscope. AKT(S473) / PKCα(S657) ; PubMed: 22139837 J Biol Chem CWR22R3 cells cultured in medium with CDS serum were treated without/with 10 nm DHT (−/+ DHT) for 4 h. The cells were immunostained for AKT or PKCα phosphorylation and examined with a confocal microscope. Bars: 20 μm	22139837

In vivo

DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan^[2].

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: Bladder cancer cells
Concentrations: 1 nM
Incubation Time: 24 h
Method:
Bladder cancer cells at a density of 50-60% confluence in 24-well plates are co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of PRL-TK-luc plasmid DNA. After 6 h of transfection, the medium is replaced with another medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF, or both) for 24 h. Cells were harvested, lysed, and assayed for luciferase activity.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: SOD1-G93A mutant mice with the congenic C57BL/6J background
Dosages: 5 mg
Administration: silastic implant
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	58 mg/mL (199.69 mM)
	Ethanol	58 mg/mL (199.69 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dihydrotestosterone (DHT) SDF

Molecular Weight	290.44
Formula	C₁₉H₃₀O₂
CAS No.	521-18-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	androstanolone, stanolone, 5α-DHT
Smiles	CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01724619	Terminated	Drug: [F-18] fluorinated dihydrotestosterone (FDHT)	Prostate Cancer	Wake Forest University Health Sciences	November 2012	Early Phase 1
NCT00490022	Completed	Drug: Dihydrotestosterone (DHT) gel (0.7%)\|Drug: Placebo gel	Healthy	University of Washington\|National Institute on Aging (NIA)\|ASCEND Therapeutics	June 2007	Phase 1\|Phase 2
NCT00062790	Completed	Drug: Dutasteride	Prostatic Hyperplasia	GlaxoSmithKline	October 2003	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Darolutamide (ODM-201) ^New

Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K_i of 11 nM. Phase 3.
Sacubitril/valsartan (LCZ696) ^New

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Endoxifen HCl ^New

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
Enzalutamide (MDV3100)

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.
Bicalutamide (ICI-176334)

Bicalutamide (ICI-176334) is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.
Apalutamide (ARN-509)

Apalutamide (ARN-509) is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM in a cell-free assay, useful for prostate cancer treatment. Phase 3.
Dehydroepiandrosterone (DHEA)

Dehydroepiandrosterone (DHEA, Prasterone, Dehydroisoandrosterone) is an important endogenous steroid hormone, which is an androgen receptor antagonist and an estrogen receptor agonist.
Galeterone

Galeterone (TOK-001) is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.
Ostarine (GTx-024)

Ostarine (GTx-024, MK-2866) is a selective androgen receptor modulator (SARM) with K_i of 3.8 nM, and is tissue-selective for anabolic organs. Phase 3.

Features:The most potent and tissue-selective in vivo activity of SARMs to date, with favorable pharmacokinetic properties.
Flutamide

Flutamide (SCH-13521) is an antiandrogen drug, with its active metablolite binding at androgen receptor with K_i values of 55 nM, and primarily used to treat prostate cancer.

Choose Your Country or Region

By Signaling Pathways

By product type

Dihydrotestosterone (DHT)